Literature DB >> 2714862

Clinical experience with pefloxacin in the therapy of typhoid fever.

P Cristiano1, G Morelli, V Briante, M R Iovene, F Simioli, P Altucci.   

Abstract

Thirty hospitalized patients (22 men and eight women), aged between 15 and 41 years (mean = 25.4 years), with severe proven typhoid sepsis were treated with pefloxacin at daily dose of 1200 mg, divided in three doses, intravenously for the first five days and orally for the following ten days of treatment. All patients completely recovered from infection and pathogens were eradicated after 30 days of follow-up. In none of the patients was a relapse registered during the follow-up or enteric carrier state after disease. Pefloxacin therapy was well tolerated by all patients: in five patients a mild and transient epigastric pain and in one patient a mild and transient nausea were registered. Pefloxacin is a safe and effective agent for therapy of typhoid fever.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714862     DOI: 10.1007/BF01646882

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Typhoid fever resistant to furazolidone, ampicillin, chloramphenicol and co-trimoxazole.

Authors:  S K Samantaray
Journal:  Indian J Med Sci       Date:  1979-01

2.  In-vitro activity of pefloxacin against micro-organisms multiply resistant to beta-lactam antibiotics and aminoglycosides.

Authors:  L Verbist
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

3.  Transferable chloramphenicol resistance in Salmonella typhi.

Authors:  C K Paniker; K N Vimala
Journal:  Nature       Date:  1972-09-08       Impact factor: 49.962

4.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

5.  Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor.

Authors:  T Butler; N N Linh; K Arnold; M Pollack
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

6.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

7.  Salmonella typhi in vivo acquires resistance to both chloramphenicol and co-trimoxazole.

Authors:  N Datta; H Richards; C Datta
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

8.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.

Authors:  A M Clarke; S J Zemcov; M E Campbell
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

10.  [Pharmacokinetic behavior of pefloxacin in man].

Authors:  J B Fourtillan
Journal:  Rev Med Interne       Date:  1986-03       Impact factor: 0.728

View more
  4 in total

Review 1.  Fluoroquinolones: use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method.

Authors:  R Janknegt
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

Review 2.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 3.  Fluoroquinolones in the treatment of typhoid fever and the carrier state.

Authors:  I Zavala Trujillo; C Quiroz; M A Gutierrez; J Arias; M Renteria
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Pefloxacin versus chloramphenicol in the therapy of typhoid fever.

Authors:  P Cristiano; L Imparato; C Carpinelli; F Lauria; M R Iovene; M F Corrado; P Maio; C Imperatore
Journal:  Infection       Date:  1995 Mar-Apr       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.